Search

We assessed vaccine-induced antibody responses to the SARS-CoV-2 ancestral virus and Omicron variant before and after booster immunization in 57 patients with B cell malignancies. Over one-third of vaccinated patients at the pre-booster time point were seronegative, and these patients were predominantly on active cancer therapies such as anti-CD20 monoclonal antibody. While booster immunization was able to induce detectable antibodies in a small fraction of seronegative patients, the overall booster benefit was disproportionately evident in patients already seropositive and not receiving active therapy. While ancestral virus- and Omicron variant-reactive antibody levels among individual patients were largely concordant, neutralizing antibodies against Omicron tended to be reduced. Interestingly, in all patients, including those unable to generate detectable antibodies against SARS-CoV-2 spike, we observed comparable levels of EBV- and influenza-reactive antibodies, demonstrating that B cell-targeting therapies primarily impair de novo but not preexisting antibody levels. These findings support rationale for vaccination before cancer treatment.

Due to the increased use and availability of herbal medicinal products, it has been necessary to perform investigations pertaining to their toxicological safety. The aim of this study was to use the rapid and sensitive technique of Single Cell Gel Electrophoresis (SCGE) or "Comet Assay" to assess the mutagenic potential of two such products: "Hypiran" and "Sankol." The results were compared against positive (hydrogen peroxide) and negative (no mutagen) control groups. The instances of DNA damage were observed in 25 randomly selected cells and viewed under a fluorescence microscope following electrophoresis and staining with ethidium bromide. Both microscopic inspection and calculation of the number of affected/damaged cells were encouraging and were comparable to the observations of previous studies using SCGE. The total instances of cell damage in the presence of "Hypiran" increased as the dose increased, with all 25 cells exhibiting fragmentation at the highest dose. However, "Sankol" only exhibited some damage (8-12% of cells) at all doses. The results obtained suggest that in vitro, "Hypiran" produces dose dependent DNA damage and therefore may possess some mutagenic potential. Compared to the positive control, no significant DNA damage was observed with "Sankol" and hence this compound may have no mutagenic potential. However, further study is required before a full evaluation of these products can be made.